US Stock MarketDetailed Quotes

HLVX HilleVax

Watchlist
  • 1.860
  • +0.030+1.64%
Close Feb 14 16:00 ET
  • 1.802
  • -0.058-3.13%
Post 17:36 ET
92.64MMarket Cap-0.60P/E (TTM)

About HilleVax Company

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Company Profile

SymbolHLVX
Company NameHilleVax
Listing DateApr 29, 2022
Issue Price17.00
Founded2020
CEODr. Robert M. Hershberg, M.D.,PhD
MarketNASDAQ
Employees90
Fiscal Year Ends12-31
Address321 Harrison Avenue,Suite 500
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02118
Phone1-617-213-5054

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Robert M. Hershberg, M.D.,PhD
  • Chairman of the Board, President and Chief Executive Officer
  • 9.70M
  • Shane Maltbie
  • Vice of President, Finance, Chief Financial Officer and Principal Accounting Officer
  • --
  • Paul S. Bavier
  • General Counsel and Chief Administrative Officer
  • --
  • Dr. Gary Dubin, M.D.
  • Director
  • --
  • Aditya Kohli, PhD
  • Director
  • 4.08M
  • Dr. Nanette Cocero, M.B.A.,PhD
  • Independent Director
  • 555.03K
  • Jeryl L. Hilleman
  • Independent Director
  • 375.11K
  • Patrick J. Heron
  • Independent Director
  • 367.11K
  • Dr. Shelley Chu, PhD
  • Independent Director
  • 355.11K
  • Dr. Jaime Sepulveda, D.Sc.,M.D.,M.P.H.
  • Independent Director
  • 353.11K
  • Dr. Julie L. Gerberding, M.D.,M.P.H.
  • Independent Director
  • 365.93K

Trending Stocks

Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More